Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-cell response after intravesical BCG instillations in superficial bladder cancer
NL-OMON35614Active, not recruiting
- Sponsor
- Microvida
- Start
- Feb 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of bcg vaccine in bladder cancer, sponsored by Microvida. Primary endpoints: Reliable and reproducible bladder cell ELISPOT development, Validation of PPD ELISPOT in bladder lavage fluid and 1 more. Started Feb 2010; status: active, not recruiting.
02
Drugs
bcg vaccine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NL-OMON35614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35614.